São Paulo, October 22, 2025 - Eurofarma, the first pharmaceutical multinational with 100% Brazilian capital, was elected winner in the Medicines & Biotechnology category of the 2025 BandNews Most Admired Brands Award, consolidating itself as one of the most admired and respected companies in Brazil. The award ceremony took place on Tuesday, the 21st, at the headquarters of Grupo Bandeirantes, in São Paulo.

The award is a source of pride for the company, as its dynamic is based on popular vote, reinforcing the trust that Brazilian society places in Eurofarma, especially in the work of each collaborator who helps build, daily, an innovative, ethical company committed to access to health and sustainable development.

Promoted by BandNews in partnership with the Áquila Institute, the award recognizes brands that stand out for their relevance, reputation, innovation, and positive impact on society. The victory was consolidated through a comprehensive survey with Brazilian consumers, who evaluated brands based on criteria such as reputation, trust, innovation, and positive impact on society.

This achievement further reinforces the prestige of Eurofarma, which already holds certification as a High Renown Brand by the National Institute of Industrial Property (INPI), and reaffirms public knowledge of the company's successful trajectory that combines purpose and excellence, solidity in research, biotechnology, sustainable development, and loyalty to the purpose of promoting access to health and quality of life.

About Eurofarma
Founded in 1972, Eurofarma operates in the health sector with the production and marketing of products and services to improve people's quality of life. With a focus on generating shared value, it covers the main pharmaceutical segments, such as medical prescription, generics, hospital, oncology, OTC, personal care, and animal health, in addition to providing production services to third parties. With broad coverage of therapeutic classes, the portfolio comprises more than 4,000 SKUs, serving practically all medical specialties. Leader in medical prescription in Brazil, where it also holds the vice-leadership in generics, Eurofarma is present in 24 countries, with 100% coverage in Latin America and leadership in the region's retail. It also maintains operations in the USA and Africa, counting in total more than 13.5 thousand employees and 11 factories, and accounted for 600 million units produced in 2024. In the same year, the company invested more than R$ 800 million in innovation projects and achieved net revenue exceeding R$ 11 billion.

Press Information
G&A Relações Públicas
e-mail: imprensaeurofarma@gaspar.com.br
Iza França - 11 97644-4496 (iza.franca@gaspar.com.br)
Guilherme Gaspar - 11 98285-6000